Akèy › Kansè (tout kalite) › Tennessee › Nashville
Etid klinik pou Kansè (tout kalite) nan Nashville, TN
65 etid pou Kansè (tout kalite) ap chèche patisipan nan sit nan ak bò kote Nashville (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
A Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Telisotuzumab Adizutecan, Monotherapy or in Combination With Osimertinib, Compared to Standard of Care in Adult Participants With Locally Advanced or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer
Ap rekriteFaz 2/3
- SCRI Oncology Partners /ID# 276959, Nashville
A Study to Assess Change in Disease Activity and Adverse Events in Adult Participants With Gynecologic Cancers Receiving Intravenous Infusion of IMGN151 as Monotherapy or in Combination With Other Therapies
Ap rekriteFaz 2
- SCRI Oncology Partners /ID# 279733, Nashville
A Study of ASP3082 in Adults With Advanced Solid Tumors
Ap rekriteFaz 1
- Vanderbilt University Medical Center, Nashville
Enfortumab Vedotin in Combination With Pembrolizumab vs. Concurrent Chemoradiotherapy (cCRT) in People With Muscle Invasive Bladder Cancer (EV-309)
Ap rekriteFaz 3
- SCRI Oncology Partners, Nashville
A Study of PHN-012 in Patients With Advanced Solid Tumors
Ap rekriteFaz 1
- PHN-012-001 Site, Nashville
Registry Study for Radiation Therapy Outcomes
Ap rekriteEtid obsèvasyon
- Tennessee Oncology Proton Center, Franklin · 17 mi lwen
uTRACT Jelmyto Registry: A Registry of Patients With Upper Tract Urothelial Cancer (UTUC) Treated With Jelmyto
Ap rekriteEtid obsèvasyon
- Vanderbilt University Medical Center, Nashville
A Study of GSK5764227 in Combination With Standard of Care (SoC) or Other Agents in Participants With Advanced Solid Tumors
Ap rekriteFaz 1
- GSK Investigational Site, Nashville
Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing
Ap rekriteEtid obsèvasyon
- Vanderbilt University Medical Center, Nashville
A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue
Ap rekriteFaz 2/3
- Henry-Joyce Cancer Clinic, Nashville
A Study of JNJ-88549968 for the Treatment of Calreticulin (CALR)-Mutated Myeloproliferative Neoplasms
Ap rekriteFaz 1
- Sarah Cannon Cancer Institute, Nashville
A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
Ap rekriteFaz 3
- Sarah Cannon Research Institute, Nashville
- United States Oncology Regulatory Affairs Corporate Office, Nashville
A Study of NEOK001, a B7-H3 and ROR1 Targeting Bispecific ADC in Participants With Select Solid Tumors
Ap rekriteFaz 1
- SCRI Oncology Partners, Nashville
A Study of JNJ-87890387 for Advanced Solid Tumors
Ap rekriteFaz 1
- Sarah Cannon Research Institute, Nashville
A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer
Ap rekriteFaz 3
- Vanderbilt University Medical Center, Nashville
Pivotal Open-label Phase 3 Clinical Study of QTX-2101 in Adult Patients With Acute Promyelocytic Leukemia
Ap rekriteFaz 3
- Quetzal Site 12, Nashville
A Study to Evaluate Adverse Events and Change in Disease Activity of Intravenous ABBV-706 Versus Standard of Care in Adult Participants With Relapsed/Refractory Small Cell Lung Cancer
Ap rekriteFaz 3
- SCRI Oncology Partners /ID# 279779, Nashville
- Vanderbilt University Medical Center /ID# 280169, Nashville
Pan Tumor Rollover Study
Ap rekriteFaz 2
- Tennesse Oncology, Nashville
Extension Study for Participants in Studies That Include Belzutifan (MK-6482-043/LITESPARK-043)
Ap rekriteFaz 3
- SCRI Oncology Partners ( Site 7000), Nashville
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
Ap rekriteFaz 2
- Tennessee Oncology - Nashville / Sarah Cannon Research Institute, Nashville
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
Ap rekriteFaz 1/2
- Sarah Cannon Research Institue, Nashville
Long-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells
Ap rekriteFaz 2/3
- Sarah Cannon Research Inst, Nashville
A Study to Investigate the Safety and Preliminary Efficacy of GSK5460025 Alone or in Combination With Other Anti-cancer Agents in Participants With Solid Tumors
Ap rekriteFaz 1/2
- GSK Investigational Site, Nashville
A Phase 1/1b Study of IAM1363 in HER2 Cancers
Ap rekriteFaz 1
- SCRI Oncology Partners, Nashville
- Vanderbilt Ingram Cancer Center, Nashville
A Study to Evaluate Safety, Tolerability and Preliminary Activity of AGX101 in Participants With Advanced Solid Tumors
Ap rekriteFaz 1
- Sarah Cannon Research Center, Nashville
Study of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due to ER+/HER-2- Breast Cancer
Ap rekriteFaz 1/2
- SCRI Oncology Partners, Nashville
A Phase IIIb Study to Evaluate Camizestrant Plus Ribociclib in ER-positive, HER2-negative Advanced Breast Cancer
Ap rekriteFaz 3
- Research Site, Nashville
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
Ap rekriteFaz 3
- Tennessee Oncology, Nashville
- USO - US Oncology Research Network, Nashville
A Longitudinal Multi-Omic Biomarker Profiling Study of Patients With Head & Neck Squamous Cell Carcinoma (HNSCC)
Ap rekriteEtid obsèvasyon
- Vanderbilt University, Nashville
Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal Cancer With KRAS p.G12C Mutation
Ap rekriteFaz 3
- Tennessee Oncology PLLC - Chattanooga, Nashville
- Tennessee Oncology, PLLC, Nashville
- Vanderbilt University Medical Center, Nashville
Project: Every Child for Younger Patients With Cancer
Ap rekriteEtid obsèvasyon
- The Children's Hospital at TriStar Centennial, Nashville
- Vanderbilt University/Ingram Cancer Center, Nashville
FOG-001 in Locally Advanced or Metastatic Solid Tumors
Ap rekriteFaz 1/2
- Sarah Cannon Research Institute, Nashville
- Vanderbilt Ingram Cancer Center, Nashville
A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
Ap rekriteFaz 1/2
- Sarah Cannon Research Institute Oncology Partners (SCRI-Nashville), Nashville
Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer
Ap rekriteFaz 3
- Vanderbilt Breast Center at One Hundred Oaks, Nashville
- Vanderbilt University/Ingram Cancer Center, Nashville
- Vanderbilt-Ingram Cancer Center at Franklin, Franklin · 17 mi lwen
- ak 1 plis
A Study of CHS-114 (Tagmokitug) in Combination With Toripalimab and/or Other Treatments in Participants With Advanced Solid Tumors
Ap rekriteFaz 1
- SCRI Oncology Partners, Nashville
Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors
Ap rekriteFaz 1/2
- Sara Cannon Research Institute Tennessee, Nashville
A Study to Assess Adverse Events of Intravenously (IV) Infused Etentamig (ABBV-383) in Adult Participants With Relapsed or Refractory Multiple Myeloma
Ap rekriteFaz 1
- Vanderbilt Ingram Cancer Center /ID# 252470, Nashville
A Study to Assess Adverse Events and Change in Disease Activity in Adult Participants Receiving Intravenously Infused Telisotuzumab Adizutecan Alone or With Standard of Care in Participants With Post Adjuvant Circulating Tumor DNA Positive Colorectal Cancer and No Radiographic Evidence of Disease
Ap rekriteFaz 2
- SCRI Oncology Partners /ID# 274522, Nashville
First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
Ap rekriteFaz 1/2
- Sarah Cannon Research Institute, Nashville
Trial of Orca-T Following Reduced Intensity or Nonmyeloablative Conditioning in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome
Ap rekriteFaz 2
- Vanderbilt University, Ingram Cancer Center, Nashville
Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC
Ap rekriteFaz 1/2
- Tennessee Oncology, Nashville
Pilot Study Evaluating Panitumumab-IRDye800 as an Optical Imaging Agent to Detect Intracranial Lesions During Neurosurgical Procedures
Ap rekriteFaz 1 bonè
- Vanderbilt University Medical Center, Nashville
A Study to Evaluate the Safety,Tolerability, Pharmacokinetics and Clinical Activity of Mocertatug Rezetecan for Injection in Participants With Advanced Solid Tumors (BEHOLD-1)
Ap rekriteFaz 1
- GSK Investigational Site, Nashville
A Trial of RSC-1255 for Treatment of Patients With Advanced Malignancies
Ap rekriteFaz 1
- Sarah Cannon, SCRI Oncology Partners, Nashville
CT-95 in Advanced Cancers Associated With Mesothelin Expression
Ap rekriteFaz 1
- Context Investigational Site, Nashville
A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression
Ap rekriteFaz 1/2
- Vanderbilt University Medical Center, Nashville
A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations
Ap rekriteFaz 1
- Research Site, Nashville
Galleri® in the Medicare Population.
Ap rekriteVolontè an sante akeyi
- HCA Healthcare Centennial, Nashville
- HCA Healthcare Nashville, Nashville
- HCA Healthcare Brentwood, Brentwood · 9 mi lwen
A Study of GSK5764227 in Participants With Advanced Solid Tumors (EMBOLD)
Ap rekriteFaz 1
- GSK Investigational Site, Nashville
Study Evaluating [18F]NOTA-ABY030 for Safety and Tolerability of Indeterminate Primary and/or Metastatic Disease in Head and Neck Squamous Cell Carcinoma
Ap rekriteFaz 1
- Vanderbilt University Medical Center, Nashville
A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-130037 in Participants With Advanced Solid Tumors
Ap rekriteFaz 1
- Sarah Cannon Research Institute, Nashville
Pilot Study of [68Ga]Ga-ABY-025 Imaging in Patients Undergoing Treatment With HER2-targeted Therapy
Ap rekriteFaz 1 bonè
- Vanderbilt University Medical Center, Nashville
High-Resolution PET-CT Imaging for Surgical Margin Visualization
Ap rekrite
- Vanderbilt University Medical Center, Nashville
A Study to Investigate the Safety and Efficacy of NST-628 Oral Tablets in Subjects With Solid Tumors
Ap rekriteFaz 1
- SCRI Oncology Partners, Nashville
- Vanderbilt-Ingram Cancer Center, Nashville
A Phase 1 Study of CPO301 in Adult Patients With Advanced or Metastatic Solid Tumors
Ap rekriteFaz 1
- SCRI Oncology Partners, Nashville
Suprachoroidal Administration in Subjects With Metastases to the Choroid
Ap rekriteFaz 2
- Tennessee Retina, PC, Nashville
A Study of YL242 in Subjects With Advanced Solid Tumors
Ap rekriteFaz 1/2
- US-205, Nashville
Evaluation of RBS2418 in Subjects With Advanced, Metastatic Solid Tumors
Ap rekriteFaz 1
- Vanderbilt-Ingram Cancer Center, Nashville
A Study of ERAS-4001 in Patients With Advanced or Metastatic Solid Tumors.
Ap rekriteFaz 1
- Sarah Cannon Research Institute (SCRI) Oncology Partners, Nashville
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Ap rekriteEtid obsèvasyon
- Massive Bio SYNERGY-AI site, Nashville
Inherited CAncer REgistry
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
- Vanderbilt-Ingram Cancer Center, Nashville
A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors
Ap rekriteFaz 1/2
- Sarah Cannon Research Institute, Nashville
A Trial of AMXI-5001 for Treatment in Patients With Advanced Malignancies
Ap rekriteFaz 1/2
- SCRI Oncology Partners, Nashville
A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies
Ap rekriteFaz 1/2
- Verdi Oncology Tennessee, Scri Oncology Partners, Nashville
Registry Study for Proton Therapy Clinical Outcomes and Long-Term Follow-up
Ap rekriteEtid obsèvasyon
- Provision CARES Proton Therapy Nashville, Franklin · 17 mi lwen
Etid Kansè (tout kalite) nan lòt vil
- Houston, TX121 etid
- New York City, NY109 etid
- Boston, MA85 etid
- Los Angeles, CA74 etid
- Philadelphia, PA59 etid
- Washington, DC58 etid
- Durham, NC58 etid
- Chicago, IL51 etid
- Atlanta, GA49 etid
- Seattle, WA49 etid
- Arlington, VA48 etid
- St. Louis, MO46 etid
Lòt etid nan Nashville
- Kansè Poumon ki pa ti selil97 etid
- Kansè nan tete81 etid
- Kansè Metastatik70 etid
- Kansè kolorektal69 etid
- Kansè ovè49 etid
- Kansè pwostat43 etid
- Kansè poumon40 etid
- Karsinòm selil skuamèz tèt ak kou39 etid
- Kansè pankreyas39 etid
- Kansè Endomèt38 etid
- Melanom33 etid
- Myelom Miltip32 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 6, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.